
## Did you know?

What prostate cancer looks like today

Prostate cancer is the fourth most commonly diagnosed cancer worldwide1



**30-41%** of cancers<sup>2</sup>

MRI-targeted biopsies have been shown to improve

diagnosis of high-risk cancers by **30%**<sup>3</sup>

Reducing unnecessary biopsies can enhance the

patient experience by reducing post-procedure complications<sup>4</sup>

Due to inaccurate risk profiling

Up to 40% of aggressive prostate cancers are undertreated<sup>5</sup>

Up to **50%** of insignificant prostate cancers are **overtreated**<sup>6</sup>



Research suggests that **prostate** cancer is most prevalent in men of African descent, compared to men of European or Asian descent<sup>7</sup>



Philips solutions for prostate diagnosis are in use at 22 of the 25 top-ranked us cancer hospitals<sup>8</sup>



## **Discover how Philips can help support your** prostate cancer program: www.philips.com/prostatesolutions

- analysis, Clim Generation Constant Sep 13. PMID: 30415878. 3. Siddiqui MM, et al. Comparison of MR/ultrasound fusion–guided biopsy with ultrasound-guided bioscu for the fliagnosis of prostate cancer. JAMA. 2015;313(4):390-397.
- sys for the diagnosis of prostate cancer. JAMA. 2015;313(4):390-397. agadda VK, et al. MRI/US fusion-guided prostate biopsy allows for equivalent cancer detection